A HER2-targeted RNA aptamer molecule labeled with 99mTc for single-photon imaging in malignant tumors

Nuclear Medicine and Biology

Volumn 40, Issue 8, 2013, Pages 980-986

  Varmira, Kambiz ^a   Hosseinimehr, Seyed Jalal ^a   Noaparast, Zohreh ^a   Abedi, Seyed Mohammad ^a  

^a MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

99mTc; Aptamer; HER2; Radionuclide; Specific binding

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; RADIOPHARMACEUTICAL AGENT; TECHNETIUM HYNIC RNA APTAMER TC 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL STRAIN MCF 7; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DISSOCIATION CONSTANT; DRUG CLEARANCE; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG PURITY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

(99M)TC; APTAMER; HER2; RADIONUCLIDE; SPECIFIC BINDING;

ANIMALS; APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL LINE, TUMOR; FEMALE; HUMANS; ISOTOPE LABELING; MICE; MOLECULAR IMAGING; OVARIAN NEOPLASMS; PHOTONS; RECEPTOR, ERBB-2; TECHNETIUM;

EID: 84886294912     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.07.004     Document Type: Article

References (35)

1. Seidenfeld J., Samsom D.J., Rothenberg B.M., Bonnell C.J., Ziegler K.M., Aronson N. HER2 testing to manage patients with breast cancer or other solid tumors. Evid Rep Technol Assess (Full Rep) 2008, 1-362.
2. Jakobovits A. Monoclonal antibody therapy for prostate cancer. Handb Exp Pharmacol 2008, 237-256.
3. Mass R.D. The HER, receptor family: a rich target for therapeutic development. Int J Radiat Oncol Biol Phys 2004, 58:932-940.
4. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat Rev Clin Oncol 2011, 9:16-32.
5. Verri E., Guglielmini P., Puntoni M., Perdelli L., Papadia A., Lorenzi P., et al. HER2/neu oncoprotein overexpression in epithelial ovarian cancer: evaluation of its prevalence and prognostic significance. Clinical study. Oncology 2005, 68:154-161.
6. Shi Y., Brands F.H., Chatterjee S., Feng A.C., Groshen S., Schewe J., et al. Her-2/neu expression in prostate cancer: high level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 2001, 166:1514-1519.
7. Tolmachev V., Stone-Elander S., Orlova A. Radiolabelled receptor-tyrosine-kinase targeting drugs for patient stratification and monitoring of therapy response: prospects and pitfalls. Lancet Oncol 2010, 11:992-1000.
8. Lub-de Hooge M.N., Kosterink J.G.W., Perik P.J., Nijnuis H., Tran L., Bart J., et al. Preclinical characterisation of 111In-DTPA-trastuzumab. Br J Pharmacol 2004, 143:99-106.
9. Tang Y.S.D., Chen P., Wang J., Holloway C., Reilly R.M. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments. Nucl Med Commun 2005, 26:427-432.
10. Wallberg H., Orlova A., Altai M., Hosseinimehr S.J., Widstrom C., Malmberg J., et al. Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 2011, 52:461-469.
11. Famulok M., Hartig J.S., Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy. Chem Rev 2007, 107:3715-3743.
12. Vorhies J.S., Nemunaitis J.J. Nucleic acid aptamers for targeting of shRNA-based cancer therapeutics. Biologics 2007, 1:367-376.
13. Yigit M.V., Mazumdar D., Kim H.K., Lee J.H., Odintsov B., Lu Y. Smart "turn-on" magnetic resonance contrast agents based on aptamer-functionalized superparamagnetic iron oxide nanoparticles. Chembiochem 2007, 8:1675-1678.
14. Lee J.F., Stovall G.M., Ellington A.D. Aptamer therapeutics advance. Curr Opin Chem Biol 2006, 10:282-289.
15. Gao H., Qian J., Yang Z., Pang Z., Xi Z., Cao S., et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 2012, 33:6264-6272.
16. Ni X., Castanares M., Mukherjee A., Lupold S.E. Nucleic acid aptamers: clinical applications and promising new horizons. Curr Med Chem 2011, 18:4206-4214.
17. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J., et al. Tumor targeting by an aptamer. J Nucl Med 2006, 47:668-678.
18. Wang A.Z., Bagalkot V., Vasilliou C.C., Gu F., Alexis F., Zhang L., et al. Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem 2008, 3:1311-1315.
19. Pieve C.D., Perkins A.C., Missailidis S. Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 2009, 36:703-710.
20. Kim M.Y., Jeong S. In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 2011, 21:173-178.
21. Persson M., Tolmachev V., Andersson K., Gedda L., Sandstrom M., Carlsson J. [(177)Lu]pertuzumab: experimental studies on targeting of HER-2 positive tumour cells. Eur J Nucl Med Mol Imaging 2005, 32:1457-1462.
22. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998, 273:20556-20567.
23. Dupont D.M., Madsen J.B., Hartmann R.K., Tavitian B., Duconge F., Kjems J., et al. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding. RNA 2010, 16:2360-2369.
24. Chan S.D., Antoniucci D.M., Fok K.S., Alajoki M.L., Harkins R.N., Thompson S.A., et al. Heregulin activation of extracellular acidification in mammary carcinoma cells is associated with expression of HER2 and HER3. J Biol Chem 1995, 270:22608-22613.
25. Zielinski R, Hassan M, Lyakhov I, Needle D, Chernomordik V, Garcia-Glaessner A, et al. Affibody-DyLight conjugates for in vivo assessment of HER2 expression by near-infrared optical imaging. PLoS One;7:e41016.
26. Lattrich C., Juhasz-Boess I., Ortmann O., Treeck O. Detection of an elevated HER2 expression in MCF-7 breast cancer cells overexpressing estrogen receptor beta1. Oncol Rep 2008, 19:811-817.
27. Tolmachev V., Tran T.A., Rosik D., Sjoberg A., Abrahmsen L., Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med 2012, 53:953-960.
28. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
29. Samaranayake H., Wirth T., Schenkwein D., Raty J.K., Yla-Herttuala S. Challenges in monoclonal antibody-based therapies. Ann Med 2009, 41:322-331.
30. Weinberg W.C., Frazier-Jessen M.R., Wu W.J., Weir A., Hartsough M., Keegan P., et al. Development and regulation of monoclonal antibody products: challenges and opportunities. Cancer Metastasis Rev 2005, 24:569-584.
31. Wang W., Singh S., Zeng D.L., King K., Nema S. Antibody structure, instability, and formulation. J Pharm Sci 2007, 96:1-26.
32. Da Rocha Gomes S., Miguel J., Azema L., Eimer S., Ries C., Dausse E., et al. (99m)Tc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug Chem 2012, 23:2192-2200.
33. Schmidt K.S., Borkowski S., Kurreck J., Stephens A.W., Bald R., Hecht M., et al. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res 2004, 32:5757-5765.
34. Li Y.C., Tan T.Z., Zheng J.G., Zhang C. Anti-sense oligonucleotide labeled with technetium-99m using hydrazinonictinamide derivative and N-hydroxysuccinimidyl S-acetylmercaptoacetyltriglycline: a comparison of radiochemical behaviors and biological properties. World J Gastroenterol 2008, 14:2235-2240.
35. Hosseinimehr S.J., Tolmachev V., Orlova A. Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design. Drug Discov Today 2012, 17:1224-1232.